Literature DB >> 7911665

Regression of collagen-induced arthritis with taxol, a microtubule stabilizer.

E Brahn1, C Tang, M L Banquerigo.   

Abstract

OBJECTIVE: To investigate the capacity of taxol, a microtubule stabilizer, to inhibit collagen-induced arthritis (CIA), a model of rheumatoid arthritis.
METHODS: Louvain rats were immunized with type II collagen (day 0) to induce arthritis. Taxol was administered beginning on day 2 (prevention protocol) or at arthritis onset on day 9 (in either a high-dose or low-dose suppression protocol). Rats were assessed clinically and radiographically for arthritis severity. Cellular and humoral immune responses to type II collagen were also evaluated.
RESULTS: Institution of taxol prior to arthritis onset completely precluded the development of CIA (P < 0.0001 versus controls). It also suppressed established clinical disease (high-dose protocol P < 0.0000001; low-dose protocol P < 0.0001) and radiographic erosions (high-dose protocol P < 0.00001; low-dose protocol P < 0.001) compared with controls. Levels of IgG antibodies, but not delayed-type hypersensitivity, to type II collagen were reduced after taxol administration.
CONCLUSION: Taxol completely prevented the induction of CIA and caused significant regression of existing arthritis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7911665     DOI: 10.1002/art.1780370611

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  19 in total

1.  Rheumatoid arthritis masked by docetaxel chemotherapy in a patient with ovarian carcinoma.

Authors:  Marc A Callender; Emmanuel S Antonarakis
Journal:  J Clin Rheumatol       Date:  2008-04       Impact factor: 3.517

Review 2.  The role of plant-derived drugs and herbal medicines in healthcare.

Authors:  P A De Smet
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

3.  Calcium pyrophosphate dihydrate crystals activate MAP kinase in human neutrophils: inhibition of MAP kinase, oxidase activation and degranulation responses of neutrophils by taxol.

Authors:  J K Jackson; C Tudan; B Sahl; S L Pelech; H M Burt
Journal:  Immunology       Date:  1997-04       Impact factor: 7.397

Review 4.  An interplay of structure and intrinsic disorder in the functionality of peptidylarginine deiminases, a family of key autoimmunity-related enzymes.

Authors:  Mohammed Alghamdi; Khaled A Al Ghamdi; Rizwan H Khan; Vladimir N Uversky; Elrashdy M Redwan
Journal:  Cell Mol Life Sci       Date:  2019-07-24       Impact factor: 9.261

5.  Paclitaxel ameliorates fibrosis in hepatic stellate cells via inhibition of TGF-beta/Smad activity.

Authors:  Jun Zhou; De-Wu Zhong; Qun-Wei Wang; Xiong-Ying Miao; Xun-Di Xu
Journal:  World J Gastroenterol       Date:  2010-07-14       Impact factor: 5.742

6.  Control of myofibroblast differentiation by microtubule dynamics through a regulated localization of mDia2.

Authors:  Nathan Sandbo; Caitlyn Ngam; Elizabeth Torr; Steve Kregel; Jacob Kach; Nickolai Dulin
Journal:  J Biol Chem       Date:  2013-04-11       Impact factor: 5.157

7.  Involution of collagen-induced arthritis with an angiogenesis inhibitor, PPI-2458.

Authors:  Ernest Brahn; Nathan Schoettler; Sarah Lee; Mona L Banquerigo
Journal:  J Pharmacol Exp Ther       Date:  2009-02-13       Impact factor: 4.030

Review 8.  Bacterial and human peptidylarginine deiminases: targets for inhibiting the autoimmune response in rheumatoid arthritis?

Authors:  Pamela Mangat; Natalia Wegner; Patrick J Venables; Jan Potempa
Journal:  Arthritis Res Ther       Date:  2010-06-02       Impact factor: 5.156

9.  PLGA nanoparticles stabilized with cationic surfactant: safety studies and application in oral delivery of paclitaxel to treat chemical-induced breast cancer in rat.

Authors:  V Bhardwaj; D D Ankola; S C Gupta; M Schneider; C-M Lehr; M N V Ravi Kumar
Journal:  Pharm Res       Date:  2009-09-09       Impact factor: 4.200

10.  Disease modifying and antiangiogenic activity of 2-methoxyestradiol in a murine model of rheumatoid arthritis.

Authors:  Stacy M Plum; Eun J Park; Steve J Strawn; Elizabeth G Moore; Carolyn F Sidor; William E Fogler
Journal:  BMC Musculoskelet Disord       Date:  2009-05-01       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.